Seiji Mabuchi Selected Research

Ascites

1/2015	Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer.
12/2009	Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells.
12/2008	Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
4/2006	Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models.
11/2004	Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
5/2004	Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Seiji Mabuchi Research Topics

Disease

64	Uterine Cervical Neoplasms (Cancer of the Cervix) 04/2024 - 05/2009
64	Neoplasms (Cancer) 03/2023 - 04/2006
31	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 09/2002
17	Carcinoma (Carcinomatosis) 09/2023 - 03/2007
10	Ovarian Epithelial Carcinoma 09/2023 - 10/2012
10	Adenocarcinoma 12/2022 - 09/2010
9	Neoplasm Metastasis (Metastasis) 01/2020 - 01/2011
8	Endometrial Neoplasms (Endometrial Cancer) 05/2024 - 05/2013
6	Ascites 01/2015 - 05/2004
4	Lymphatic Metastasis 02/2023 - 01/2011
3	Margins of Excision 12/2021 - 10/2017
3	Inflammation (Inflammations) 01/2021 - 11/2013
3	Breast Neoplasms (Breast Cancer) 03/2019 - 10/2003
3	Disease Progression 01/2018 - 04/2010
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2018 - 04/2010
3	Carcinogenesis 05/2016 - 10/2003
2	Uterine Neoplasms (Uterine Cancer) 03/2023 - 01/2018
2	Fistula 04/2022 - 03/2021
2	Leukocytosis (Pleocytosis) 01/2019 - 07/2011
2	Thrombocytosis (Thrombocythemia) 01/2019 - 11/2015
2	Adenosquamous Carcinoma 03/2017 - 10/2012
2	Osteoporosis 01/2017 - 01/2009
2	Chorioamnionitis 03/2016 - 11/2013
2	Hypoxia (Hypoxemia) 05/2015 - 09/2009
2	Colorectal Neoplasms (Colorectal Cancer) 03/2010 - 02/2010
2	Hematologic Neoplasms (Hematological Malignancy) 03/2010 - 02/2010
1	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 09/2023
1	Pathologic Constriction (Stenosis) 09/2023
1	Dysmenorrhea (Menstrual Pain) 09/2023
1	Neurogenic Urinary Bladder (Bladder, Neurogenic) 02/2023
1	Rupture 02/2023
1	Abdominal Pain (Pain, Abdominal) 02/2023
1	Peritonitis 02/2023
1	Acute Abdomen 02/2023
1	Hemorrhagic Shock 04/2022
1	Gastrointestinal Hemorrhage (Hematochezia) 04/2022
1	Uterine Cervical Dysplasia 01/2022
1	Anemia 01/2022

Drug/Important Bio-Agent (IBA)

13	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2022 - 04/2010
13	Cisplatin (Platino)FDA LinkGeneric 11/2018 - 03/2004
12	Paclitaxel (Taxol)FDA LinkGeneric 01/2019 - 09/2002
10	Indicators and Reagents (Reagents)IBA 12/2021 - 07/2011
8	Carboplatin (JM8)FDA LinkGeneric 01/2017 - 05/2009
7	PlatinumIBA 10/2019 - 05/2009
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2016 - 03/2007
6	Estrogens (Estrogen)FDA Link 03/2019 - 10/2003
6	nedaplatinIBA 08/2015 - 12/2009
5	Bevacizumab (Avastin)FDA Link 04/2022 - 12/2008
4	TOR Serine-Threonine KinasesIBA 12/2020 - 03/2007
4	Estrogen ReceptorsIBA 03/2019 - 01/2004
4	Neutralizing AntibodiesIBA 03/2019 - 07/2014
4	Irinotecan (Camptosar)FDA LinkGeneric 01/2019 - 06/2014
4	Interleukin-6 (Interleukin 6)IBA 01/2019 - 11/2013
4	MicroRNAs (MicroRNA)IBA 11/2018 - 05/2013
4	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 04/2015 - 09/2002
4	Everolimus FDA Link 07/2011 - 03/2007
3	Hemoglobins (Hemoglobin)IBA 01/2022 - 03/2015
3	Raloxifene Hydrochloride (Evista)FDA Link 01/2017 - 10/2003
3	Phosphotransferases (Kinase)IBA 05/2016 - 01/2002
3	Monoclonal AntibodiesIBA 03/2010 - 12/2008
2	Dinoprostone (PGE2)FDA Link 12/2020 - 11/2018
2	PM 01183IBA 10/2019 - 01/2016
2	Celecoxib (Celebrex)FDA Link 01/2019 - 11/2018
2	VitronectinIBA 11/2018 - 10/2017
2	perifosineIBA 12/2017 - 04/2015
2	taxaneIBA 12/2017 - 05/2009
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 10/2017 - 05/2015
2	IntegrinsIBA 10/2017 - 05/2013
2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 07/2016 - 01/2002
2	CytokinesIBA 03/2016 - 11/2013
2	Antineoplastic Agents (Antineoplastics)IBA 01/2016 - 12/2009
2	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2015 - 11/2013
2	TrabectedinIBA 06/2014 - 07/2011
2	AntigensIBA 03/2010 - 02/2010
2	BAY 11-7085IBA 11/2004 - 05/2004
2	Telomerase (Telomerase Reverse Transcriptase)IBA 06/2004 - 10/2003
1	ethyleneIBA 09/2023
1	vinyl acetateIBA 09/2023
1	Anti-Bacterial Agents (Antibiotics)IBA 02/2023
1	Asu(1,6)- argipressin (VAS-A)IBA 01/2022

Therapy/Procedure

30	Radiotherapy 02/2023 - 05/2009
21	Therapeutics 05/2024 - 01/2008
21	Hysterectomy 04/2024 - 11/2011
18	Drug Therapy (Chemotherapy) 04/2022 - 05/2009
13	Chemoradiotherapy 01/2022 - 12/2009
9	Lymph Node Excision (Lymph Node Dissection) 02/2023 - 10/2012
7	Brachytherapy 03/2019 - 01/2010
5	Adjuvant Radiotherapy 03/2013 - 11/2011
3	Trachelectomy 09/2023 - 01/2017
3	Aftercare (After-Treatment) 01/2022 - 02/2015
3	Traction 01/2021 - 01/2020
3	Salvage Therapy 11/2016 - 10/2013
3	Cytoreduction Surgical Procedures 06/2014 - 03/2010
2	Neoadjuvant Therapy 09/2023 - 06/2016
2	Minimally Invasive Surgical Procedures 08/2023 - 05/2023
2	Kampo Medicine (Kampo) 01/2022 - 01/2018
2	Consolidation Chemotherapy 01/2017 - 05/2016
2	Splenectomy 12/2015 - 07/2014
1	Robotic Surgical Procedures 03/2023
1	Salpingo-oophorectomy 04/2022